scholarly journals HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis

Oncotarget ◽  
2016 ◽  
Vol 7 (39) ◽  
pp. 63571-63582 ◽  
Author(s):  
Qian-Qian Xu ◽  
Bo Pan ◽  
Chang-Jun Wang ◽  
Yi-Dong Zhou ◽  
Feng Mao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Prognostic Factor ◽  
Adjuvant Treatment ◽  
Meta Analysis ◽  
Her2 Amplification ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

2020 ◽  
Vol 84 ◽  
pp. 101965 ◽  
Author(s):  
Francesco Schettini ◽  
Tomás Pascual ◽  
Benedetta Conte ◽  
Nuria Chic ◽  
Fara Brasó-Maristany ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Pathological Complete Response ◽  
Meta Analysis ◽  
Complete Response ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis

The Breast ◽  
2020 ◽  
Vol 54 ◽  
pp. 203-210
Author(s):  
Paul Stewart ◽  
Phillip Blanchette ◽  
Prakesh S. Shah ◽  
Xiang Y. Ye ◽  
R. Gabriel Boldt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
One Year ◽  
Positive Breast Cancer

Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 522-522 ◽  
Author(s):  
Paul Stewart ◽  
Phillip S. Blanchette ◽  
Prakesh S Shah ◽  
Xiang Y Ye ◽  
R Gabriel Boldt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Er Positive ◽  
One Year ◽  
Positive Breast Cancer

522 Background: One year of adjuvant trastuzumab (T) remains the standard treatment for patients with HER2 positive breast cancer. Results from randomized trials with diverse non-inferiority margins comparing one year to a shorter duration of adjuvant T were not consistent, particularly with the PERSEPHONE and the final PHARE and Short-HER trials’ results. Our objective was to conduct a systematic review and meta-analysis of randomized trials in patients with HER2 positive breast cancer to assess whether a shorter duration of adjuvant T was non-inferior to one year of treatment. Methods: PubMed, EMBASE and The Cochrane Library were searched for eligible randomized trials. Hazard ratios (HR) for disease free and overall survival (DFS, OS) were weighted using generic inverse variance and pooled in a meta-analysis using random-effects models. The median of non-inferiority margins derived from each trial was calculated to set a non-inferiority margin of 1.29 for the pooled analysis. Subgroup analyses compared survival outcomes by estrogen receptor (ER) status, nodal status, length and timing of trastuzumab treatment. Results: Data of 11,376 patients from 5 trials were analyzed. A shorter duration of T was non-inferior to one year of therapy for DFS (HR 1.13, 95%CI 1.03-1.24) but worse for OS (HR 1.16, 95%CI 1.01-1.32). In addition, the non-inferiority for DFS was met for patients with ER positive disease (HR 1.1, 95%CI 0.95-1.28) and patients treated with 6 months (HR 1.09, 95%CI 0.98-1.22) or sequential T (HR 0.97, 95%CI 0.75-1.27). Conversely, the non-inferiority for DFS was not met for patients with ER negative disease (HR 1.22, 95%CI 1.06-1.41), patients treated with 9 weeks (HR 1.26, 95%CI 1.02-1.55) or concomitant T (HR 1.25, 95%CI 1.07-1.45) and patients with node negative (HR 1.12, 95% 0.93-1.35) or positive (HR 1.16, 95%CI 0.99-1.36) disease. Conclusions: Within the limitations of the available data and the different non-inferiority margins used in randomized trials, a shorter duration of adjuvant T is non-inferior to one year of therapy for DFS in patients with HER2 positive breast cancer, particularly in patients with ER positive disease. Further trials with appropriately chosen non-inferiority margins are needed to confirm the optimal duration of T in patients with low-risk disease.

scholarly journals Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis

The Breast ◽  
2011 ◽  
Vol 20 (6) ◽  
pp. 485-490 ◽  
Author(s):  
Antonis Valachis ◽  
Davide Mauri ◽  
Nikolaos P. Polyzos ◽  
Grigoris Chlouverakis ◽  
Dimitrios Mavroudis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Neoadjuvant Chemotherapy ◽  
Meta Analysis ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document